RPA43 Antibody

What is RPA43 and why is it important in molecular biology research?

RPA43 (also known as TWISTNB) is a crucial subunit of the RNA polymerase I (Pol I) complex that catalyzes the transcription of ribosomal DNA (rDNA) into ribosomal RNA (rRNA) precursors. It plays a central role in recruiting Pol I to rDNA promoters through its interaction with the transcription initiation factor Rrn3/TIF-IA . This interaction is essential for the formation of the pre-initiation complex on rDNA promoters. RPA43 is evolutionarily conserved from yeast to humans, with a highly conserved central domain (approximately residues P42-D172 in Saccharomyces cerevisiae), suggesting its fundamental importance in eukaryotic rDNA transcription mechanisms . As ribosome biogenesis is tightly regulated and often dysregulated in cancer cells, studying RPA43 provides insights into both normal cellular functions and disease mechanisms.

How specific are commercially available RPA43 antibodies across different species?

Commercial RPA43 antibodies exhibit varying degrees of cross-reactivity across species. The search results show antibodies with reactivity to human samples, while others are specific to model organisms like mouse (mRPA43) or various yeast species including Saccharomyces and Schizosaccharomyces . This species-specificity is expected given that while the central domain of RPA43 is highly conserved, there are still significant differences between orthologues. For example, approximately 23% identity and 58% similarity exist between S. cerevisiae and human sequences in the conserved region . When selecting an RPA43 antibody, researchers should carefully verify the reactivity information provided by manufacturers to ensure compatibility with their experimental model organism.

What are the key applications for RPA43 antibodies in research?

RPA43 antibodies are primarily utilized in several key applications:

• Western Blot (WB): The most common application, used to detect and quantify RPA43 protein levels in cell or tissue lysates

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection of RPA43

• Immunohistochemistry (IHC): To visualize RPA43 distribution in tissue sections

• Flow Cytometry (FCM): For analyzing RPA43 in individual cells

• Immunoprecipitation (IP): For isolating RPA43 and its interacting partners

These applications enable researchers to investigate RPA43 expression patterns, subcellular localization, protein-protein interactions, and post-translational modifications in various experimental contexts.

What are the optimal dilution ratios for different RPA43 antibody applications?

Based on the search results, recommended dilution ratios for RPA43 antibodies vary by application:

How should RPA43 antibodies be stored to maintain activity?

RPA43 antibodies should typically be stored at -20°C for optimal stability, with an expected shelf life of approximately one year under proper storage conditions . Most commercial preparations are supplied in a stabilizing solution containing PBS with 50% glycerol and 0.02% sodium azide to prevent microbial growth and maintain antibody integrity . Repeated freeze-thaw cycles should be avoided as they can lead to protein denaturation and loss of antibody function. For working solutions, short-term storage at 4°C (up to one week) is generally acceptable, but long-term storage should revert to -20°C. Always refer to manufacturer-specific storage recommendations, as formulations may vary between suppliers.

What controls should be included when validating RPA43 antibody specificity?

When validating RPA43 antibody specificity, several controls should be implemented:

• Positive control: Samples known to express RPA43 (e.g., cell lines with high nucleolar activity)

• Negative control: Samples with no or minimal RPA43 expression

• Peptide competition assay: Pre-incubation of the antibody with the immunizing peptide should abolish specific signal

• RPA43 knockdown/knockout validation: Comparing signal between wild-type and RPA43-depleted samples

• Secondary antibody-only control: To assess background from secondary antibody

• Isotype control: Using an irrelevant antibody of the same isotype to assess non-specific binding

For polyclonal antibodies, which may recognize multiple epitopes of RPA43, validation is particularly important to ensure specificity, as these antibodies are generated from rabbit antisera purified by affinity chromatography using epitope-specific immunogens .

What is known about the functional domains of RPA43 and how do antibodies target these regions?

The RPA43 protein contains several functionally important domains that are relevant to antibody targeting:

• Conserved central domain (residues P42-D172 in S. cerevisiae): This region shows strong homology across species and contains a highly conserved 15-residue motif present in all analyzed eukaryotic sequences .

• Rrn3-interaction domain: A specific region within RPA43 that mediates binding to the transcription factor Rrn3, which is critical for RNA polymerase I recruitment to rDNA promoters .

• C-terminal domain: The acidic C-terminus, though not essential for the protein's basic function, may play regulatory roles .

Most commercial antibodies are raised against synthetic peptides derived from specific regions of human RPA43 . The choice of epitope can significantly impact an antibody's utility for different applications. For instance, antibodies targeting the conserved central domain may show greater cross-reactivity across species, while those targeting variable regions provide species specificity. When investigating protein-protein interactions, researchers should select antibodies that don't target interaction interfaces to avoid epitope masking.

How can RPA43 antibodies be used to study nucleolar stress and cancer biology?

RPA43 antibodies provide valuable tools for investigating nucleolar stress and cancer biology:

• Nucleolar stress monitoring: Changes in RPA43 localization or levels can indicate nucleolar stress, a condition linked to p53 activation and cell cycle arrest. Using RPA43 antibodies in immunofluorescence studies allows visualization of nucleolar integrity and stress responses.

• Cancer research applications: Pleiomorphic nucleoli have been a marker of malignancy for over a century, reflecting the high rate of ribosome biogenesis in cancer cells . RPA43 antibodies can help quantify changes in RNA polymerase I components in tumor samples versus normal tissues.

• Therapeutic target assessment: Recent studies have shown that targeting Pol I transcription is promising for treating hematologic malignancies . RPA43 antibodies can help evaluate the efficacy of compounds designed to disrupt the RPA43-Rrn3 interaction, which is critical for rDNA transcription initiation.

• Biomarker development: Quantifying RPA43 expression levels or post-translational modifications using specific antibodies may help develop diagnostic or prognostic biomarkers for cancers characterized by dysregulated ribosome biogenesis.

The findings that selective inhibition of rDNA transcription through targeting the RPA43-Rrn3 interface can induce nucleolar stress and promote cancer cell death highlights the potential of this pathway as a therapeutic target .

What methodological approaches can resolve contradictory RPA43 antibody results across different cell types?

When faced with contradictory RPA43 antibody results across different cell types or experimental conditions, researchers should consider these methodological approaches:

• Antibody validation across cell types: Use multiple antibodies targeting different RPA43 epitopes to confirm observations. Differential post-translational modifications or protein-protein interactions in different cell types may mask epitopes.

• Expression level normalization: RPA43 expression varies significantly across tissues, with higher expression reported in fetal lung, liver, and kidney, and lower expression in most adult tissues . Normalization to appropriate housekeeping genes or proteins is essential for comparative analyses.

• Subcellular fractionation: RPA43 primarily localizes to the nucleolus and nucleoplasm . Cell-type specific differences in nucleolar organization may affect antibody accessibility. Comparing results from whole-cell lysates versus nuclear/nucleolar fractions can help resolve discrepancies.

• Cross-validation with non-antibody methods: Complement antibody-based detection with molecular techniques like RT-PCR for mRNA levels or mass spectrometry for protein detection.

• Consideration of isoforms or splice variants: Verify whether cell-type specific isoforms exist that might be differentially recognized by various antibodies.

By systematically addressing these variables, researchers can better understand whether contradictory results reflect biological differences or technical limitations of the antibodies employed.

How can RPA43 antibodies help investigate the mechanism of RNA polymerase I recruitment to rDNA promoters?

RPA43 antibodies offer several advanced approaches to study Pol I recruitment mechanisms:

• Chromatin Immunoprecipitation (ChIP): Using RPA43 antibodies in ChIP experiments allows quantification of Pol I occupancy at rDNA promoters under various conditions. This approach has revealed that RPA43 is essential for recruitment of the Pol I complex to rDNA through its interaction with Rrn3 .

• Co-immunoprecipitation (Co-IP): RPA43 antibodies can pull down intact Pol I complexes and associated factors like Rrn3. This approach has demonstrated that RPA43 and Rrn3 co-localize within the Pol I-Rrn3 complex .

• Immunoelectron microscopy: This technique has provided structural insights by showing that RPA43 and Rrn3 co-localize within the Pol I complex .

• Proximity ligation assays: For detecting in situ interactions between RPA43 and other transcription factors like Rrn3 and components of the core factor (CF) such as Rrn6.

These methodologies have collectively established that RPA43 plays a central role in bridging Pol I to the core factor via its interaction with Rrn3, which in turn interacts with the C-terminus of Rrn6 . This molecular bridging mechanism is likely conserved from yeast to humans, underscoring its fundamental importance in eukaryotic rDNA transcription.

What are the technical considerations when using RPA43 antibodies to study the effects of rRNA synthesis inhibitors?

When using RPA43 antibodies to study rRNA synthesis inhibitors, researchers should consider:

• Timing of analysis: The effects of inhibitors on RPA43 localization and Pol I complex assembly may be time-dependent. Early timepoints may reveal initial disassembly events, while later ones might show compensatory mechanisms.

• Antibody epitope accessibility: Some inhibitors specifically target the RPA43-Rrn3 interface . In such cases, epitope masking may occur if the antibody recognizes regions involved in this interaction. Using antibodies targeting different RPA43 domains can help circumvent this issue.

• Control experiments: Include positive controls such as CX-5461 or BMH-21, known Pol I inhibitors with well-characterized mechanisms, alongside experimental compounds.

• Multiparameter analysis: Combine RPA43 antibody-based detection with assays for rRNA synthesis (e.g., 5-EU incorporation), nucleolar morphology assessment, and cell viability measurements to comprehensively characterize inhibitor effects.

• Post-translational modification analysis: Some inhibitors may affect RPA43 function by altering its phosphorylation status rather than protein levels. Phospho-specific antibodies or general phosphorylation detection following RPA43 immunoprecipitation can reveal such mechanisms.

Research has shown that a 22-amino acid peptide derived from RPA43 can inhibit rDNA transcription both in vitro and in vivo by disrupting the RPA43-Rrn3 interaction, representing a novel approach to interfere with Pol I function .

How can RPA43 antibodies be used in multiplexed immunofluorescence to study nucleolar organization?

For multiplexed immunofluorescence studies of nucleolar organization using RPA43 antibodies:

• Antibody panel selection: Combine RPA43 antibodies with markers for different nucleolar compartments:

  • Fibrillar center (FC): UBF, DNA polymerase I

  • Dense fibrillar component (DFC): Fibrillarin, NOP56

  • Granular component (GC): Nucleophosmin/B23, Nucleolin

• Primary antibody host species diversification: Select RPA43 and other nucleolar marker antibodies raised in different host species (e.g., rabbit, mouse, goat) to enable simultaneous detection with species-specific secondary antibodies.

• Spectral compatibility planning: Design fluorophore combinations that minimize spectral overlap. Consider:

  • DAPI (blue): DNA staining

  • Alexa Fluor 488 (green): RPA43

  • Alexa Fluor 555/568 (red): Fibrillarin

  • Alexa Fluor 647 (far-red): Nucleophosmin

• Sequential immunostaining protocol: For antibodies from the same host species, employ sequential staining with intermediate blocking or stripping steps.

• Image acquisition optimization:

  • Use confocal microscopy with appropriate pinhole settings to capture thin optical sections

  • Employ deconvolution to improve signal-to-noise ratio

  • Consider super-resolution techniques (STED, STORM, SIM) for detailed nucleolar substructure analysis

This approach allows researchers to precisely map RPA43 localization relative to other nucleolar components under various experimental conditions, providing insights into the spatial organization of rDNA transcription machinery.

How do anti-RPA43 antibodies compare with other RNA polymerase I subunit antibodies for studying rDNA transcription?

When comparing anti-RPA43 antibodies with those targeting other Pol I subunits:

What emerging techniques are improving the specificity and sensitivity of RPA43 detection in complex samples?

Recent technical advances enhancing RPA43 detection include:

• Proximity Ligation Assay (PLA): This technique allows visualization of protein-protein interactions in situ with single-molecule sensitivity. For RPA43 research, PLA can detect interactions between RPA43 and Rrn3 or other transcription factors with higher specificity than conventional co-immunoprecipitation.

• CRISPR epitope tagging: Endogenous tagging of RPA43 with small epitopes (FLAG, HA, V5) using CRISPR-Cas9 technology allows detection with highly specific anti-tag antibodies, circumventing potential issues with direct anti-RPA43 antibody specificity.

• Single-molecule imaging: Techniques like single-molecule tracking combined with photoactivatable fluorescent proteins fused to RPA43 enable visualization of dynamic Pol I recruitment events in living cells with unprecedented temporal resolution.

• Mass cytometry (CyTOF): By conjugating RPA43 antibodies to rare earth metals, researchers can perform highly multiplexed analyses of Pol I components alongside dozens of other cellular markers with minimal spectral overlap.

• Quantitative mass spectrometry: Targeted proteomics approaches like parallel reaction monitoring (PRM) or multiple reaction monitoring (MRM) enable absolute quantification of RPA43 in complex samples with high sensitivity and specificity.

These emerging approaches are pushing the boundaries of RPA43 research beyond traditional antibody-based methods, offering new insights into the dynamics and regulation of Pol I recruitment in normal and disease states.

How might RPA43 antibodies contribute to developing novel cancer therapeutics targeting ribosomal DNA transcription?

RPA43 antibodies play several critical roles in the development of cancer therapeutics targeting rDNA transcription:

• Target validation: Immunohistochemistry with RPA43 antibodies can confirm overactivation of Pol I machinery in patient tumor samples, helping identify cancer types likely to respond to rDNA transcription inhibitors.

• High-throughput screening support: RPA43 antibodies enable development of immunoassays to screen compound libraries for molecules that disrupt the RPA43-Rrn3 interaction, building on the finding that a 22-amino acid peptide from RPA43 can selectively inhibit rDNA transcription .

• Mechanism of action studies: For lead compounds, RPA43 antibodies help elucidate whether inhibition occurs through disruption of protein-protein interactions, changes in localization, or post-translational modifications.

• Pharmacodynamic biomarker development: Quantifying changes in RPA43 nucleolar localization or complex formation can serve as pharmacodynamic biomarkers in preclinical studies and clinical trials of Pol I inhibitors.

• Combination therapy rationale: Immunofluorescence studies with RPA43 antibodies can reveal whether certain drugs enhance nucleolar stress responses, providing rationale for combination therapies.